Charles Schwab Investment Management Inc. increased its holdings in Disc Medicine, Inc. (NASDAQ:IRON – Free Report) by 2.8% during the 4th quarter, according to its most recent 13F filing with ...

Clearmind Medicine Inc., a clinical-stage biotech company, announced that its drug candidate CMND-100 has successfully arrived in the U.S., allowing the company to prepare for its FDA-approved ...

On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025Company to present further in vivo HSC preclinical data and further ...

1 Day MNMD -0.75% DJIA -0.03% Russell 2K -0.65% Health Care/Life Sciences 0.04% ...

Disc Medicine, Inc. (IRON) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Editas Medicine, Inc. before investing. In this article, we go over a few key ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...